{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:57:57Z","timestamp":1789747077072,"version":"4.0.1"},"reference-count":72,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"832","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37 CA261854"],"award-info":[{"award-number":["R37 CA261854"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA225662"],"award-info":[{"award-number":["R01 CA225662"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo Clinic Ovarian Cancer SPORE","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}]},{"name":"Mayo Clinic Ovarian Cancer SPORE Career Enhancement Award","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}]}],"content-domain":{"domain":["www.science.org"],"crossmark-restriction":true},"short-container-title":["Sci. Transl. Med."],"published-print":{"date-parts":[[2026,1,14]]},"abstract":"<jats:p>Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are an important therapy for high-grade serous ovarian cancer (HGSOC). However, PARPi resistance frequently emerges, necessitating previously unrecognized approaches to improve HGSOC responses. Here, we showed that the anaplastic lymphoma kinase (ALK) inhibitor brigatinib enhances PARPi activity in HGSOC cells by disrupting an adaptive survival mechanism orchestrated by Fos-related antigen 1 (FRA1) in response to PARPi. This effect of brigatinib occurred through an ALK-independent pathway, wherein brigatinib induced a dual blockade of focal adhesion kinase (FAK) and EPH receptor A2 (EPHA2) tyrosine kinases, leading to the suppression of protein kinase B (Akt) and extracellular-regulated kinase (ERK) signaling accompanied by disruption of a phosphorylation event crucial for FRA1 protein stability. Moreover, in HGSOC patient-derived xenograft (PDX) models, brigatinib and PARPi combination therapy induced tumor regression and improved overall survival compared with PARPi alone, particularly in models with high FAK and EPHA2. These findings support dual targeting of FAK and EPHA2 as a strategy to achieve effective and durable PARPi responses and identify a promising biomarker-based combinatorial approach using brigatinib and PARPi for HGSOC, particularly the subset characterized by high FAK and EPHA2.<\/jats:p>","DOI":"10.1126\/scitranslmed.adt8706","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:58:13Z","timestamp":1768417093000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark","source":"Crossref","is-referenced-by-count":4,"title":["Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer"],"prefix":"10.1126","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1655-066X","authenticated-orcid":true,"given":"Julie R.","family":"Duffield","sequence":"first","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9406-4747","authenticated-orcid":true,"given":"Xiaonan","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4233-1384","authenticated-orcid":true,"given":"Anjali","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9993-5654","authenticated-orcid":true,"given":"Iman K.","family":"McKeon-Makki","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3860-4024","authenticated-orcid":true,"given":"Amelia M.","family":"Huehls","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7745-1614","authenticated-orcid":true,"given":"Xinyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA."},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9464-7555","authenticated-orcid":true,"given":"Cristina","family":"Correia","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5430-8161","authenticated-orcid":true,"given":"Melissa C.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-9985","authenticated-orcid":true,"given":"Fergus J.","family":"Couch","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2539-9807","authenticated-orcid":true,"given":"Ann L.","family":"Oberg","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-7145","authenticated-orcid":true,"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry M.","family":"Karnitz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-7259","authenticated-orcid":true,"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-7683","authenticated-orcid":true,"given":"Arun","family":"Kanakkanthara","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA."},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.61"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.05.030"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70123-1"},{"key":"e_1_3_2_5_2","first-page":"1","article-title":"PARP inhibitors for ovarian cancer: Current indications, future combinations, and novel assets in development to target DNA damage repair","volume":"40","author":"Konstantinopoulos P. A.","year":"2020","unstructured":"P. A. Konstantinopoulos, S. Lheureux, K. N. Moore, PARP inhibitors for ovarian cancer: Current indications, future combinations, and novel assets in development to target DNA damage repair. Am. Soc. Clin. Oncol. Educ. Book 40, 1\u201316 (2020).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.53"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.07.001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0714"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.004"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal5148"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0607"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26947"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005627"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00454-5"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-0732"},{"key":"e_1_3_2_20_2","volume":"22","unstructured":"S. Zhang, R. Anjum, R. Squillace, S. Nadworny, T. Zhou, J. Keats, Y. Ning, S. D. Wardwell, D. Miller, Y. Song, L. Eichinger, L. Moran, W. S. Huang, S. Liu, D. Zou, Y. Wang, Q. Mohemmad, H. G. Jang, E. Ye, N. Narasimhan, F. Wang, J. Miret, X. Zhu, T. Clackson, D. Dalgarno, W. C. Shakespeare, V. M. Rivera, The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin. Cancer Res. 22, 5527\u20135538 (2016).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_21_2","volume":"53","unstructured":"C. D. McGehee, X. W. Meng, X. Wu, C. Correia, A. Venkatachalam, K. S. Flatten, K. L. Peterson, A. G. Patel, O. K. Rossman, C. Wong, R. M. Hurley, J. M. Wagner, P. A. Schneider, H. Dai, G. G. Poirier, A. E. W. Hendrickson, E. M. Swisher, A. Pandey, H. Li, S. H. Kaufmann, Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance. Nuclear Acids Res. 53, gkaf990 (2025).","journal-title":"Nuclear Acids Res."},{"key":"e_1_3_2_22_2","volume":"69","unstructured":"W. Sakai, E. M. Swisher, C. Jacquemont, K. V. Chandramohan, F. J. Couch, S. P. Langdon, K. Wurz, J. Higgins, E. Villegas, T. Taniguchi, Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69, 6381\u20136386 (2009).","journal-title":"Cancer Res."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00438-2"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27363"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0110"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63370-6"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0589"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.11.8523"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.14.3.1680-1688.1994"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.04.009"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M709934200"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6107(98)00052-2"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27275"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3396"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01776-06"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.02.018"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14768"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.91"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcab028"},{"key":"e_1_3_2_41_2","unstructured":"ARIAD Pharmaceuticals Inc. \u201cALUNBRIG (brigatinib): Highlights of prescribing information\u201d (ARIAD Pharmaceuticals Inc. 2017)."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav4508"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7549"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2598-1"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24294"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-022-00110-2"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1656"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30905-7"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw672"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-CT020"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.09.024"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.024"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1279"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5505"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00203-x"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5545"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87470-x"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12610-x"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1405"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw230"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-32-9755-5_7"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2018.07.001"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21211-6"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2017"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2611"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.04.007"},{"key":"e_1_3_2_68_2","first-page":"234","article-title":"Endpoints for mouse abdominal tumor models: Refinement of current criteria","volume":"59","author":"Paster E. V.","year":"2009","unstructured":"E. V. Paster, K. A. Villines, D. L. Hickman, Endpoints for mouse abdominal tumor models: Refinement of current criteria. Comp. Med. 59, 234\u2013241 (2009).","journal-title":"Comp. Med."},{"key":"e_1_3_2_69_2","first-page":"319","article-title":"Body condition scoring: A rapid and accurate method for assessing health status in mice","volume":"49","author":"Ullman-Cullere M. H.","year":"1999","unstructured":"M. H. Ullman-Cullere, C. J. Foltz, Body condition scoring: A rapid and accurate method for assessing health status in mice. Lab. Anim. Sci. 49, 319\u2013323 (1999).","journal-title":"Lab. Anim. Sci."},{"key":"e_1_3_2_70_2","unstructured":"Pfizer Inc. \u201cXALKORI (crizotinib): Highlights of prescribing information\u201d (Pfizer Inc. 2017)."},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.07.005"},{"key":"e_1_3_2_72_2","unstructured":"Genentech \u201cALECENSA (alectinib): Highlights of prescribing information\u201d (Genentech 2015)."},{"key":"e_1_3_2_73_2","unstructured":"Pfizer Inc. \u201cLORBRENA (lorlatinib): Highlights of prescribing Informaiton\u201d (Pfizer Inc. 2018)."}],"container-title":["Science Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/scitranslmed.adt8706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:58:31Z","timestamp":1768417111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.adt8706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":72,"journal-issue":{"issue":"832","published-print":{"date-parts":[[2026,1,14]]}},"alternative-id":["10.1126\/scitranslmed.adt8706"],"URL":"https:\/\/doi.org\/10.1126\/scitranslmed.adt8706","relation":{},"ISSN":["1946-6234","1946-6242"],"issn-type":[{"value":"1946-6234","type":"print"},{"value":"1946-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"2024-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"eadt8706"}}